Results 161 to 170 of about 98,224 (178)

Comparison of Docetaxel and Docetaxel–Irinotecan Combination as Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Randomized Phase II Trial

Annals of Oncology, 2005
S A Raptis, T Economopoulos, N Xiros
exaly  

Detailed Analysis of a Randomized Phase III Trial: Can the Tolerability of Capecitabine Plus Docetaxel Be Improved Without Compromising Its Survival Advantage?

Annals of Oncology, 2006
S Vukelja, D Maraninchi, R Leonard
exaly  

Survival and PSA Response of Patients in the TAX 327 Study Who Crossed Over to Receive Docetaxel After Mitoxantrone or Vice Versa

Annals of Oncology, 2008
Mario A Eisenberger, G R Pond, G R Pond
exaly  

Docetaxel Versus Docetaxel Alternating With Gemcitabine as Treatments of Advanced Breast Cancer: Final Analysis of a Randomised Trial

Annals of Oncology, 2010
T Wigren, R Kokko, S Pyrhonen
exaly  

Docetaxel

Reactions Weekly, 2010
openaire   +2 more sources

A Randomized Phase II Study of Sequential Docetaxel and Doxorubicin/Cyclophosphamide in Patients With Metastatic Breast Cancer

Annals of Oncology, 2002
V J Suman, J W Kugler, J N Ingle
exaly  

Phase III Trial of Gemcitabine Plus Docetaxel Versus Capecitabine Plus Docetaxel With Planned Crossover to the Alternate Single Agent in Metastatic Breast Cancer

Annals of Oncology, 2011
Adam Brufsky, M Orlando, L L Hart
exaly  

Docetaxel Is Effective in Heavily Pretreated Patients With Disseminated Nasopharyngeal Carcinoma

Annals of Oncology, 2011
Joanne Ngeow, E H Tan, B Chowbay
exaly  

Pharmacokinetics and Pharmacodynamics of Docetaxel With or Without Ketoconazole Modulation in Chemonaive Breast Cancer Patients

Annals of Oncology, 2010
B-C Goh, R Soó, S-C Lee
exaly  

Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel for Second-Line Treatment of Stage IV Non-Small-Cell Lung Cancer After Disease Progression on Platinum-Based Therapy (REVEL): A Multicentre, Double-Blind, Randomised Phase 3 Trial

Lancet, The, 2014
Sergey Orlov, Edward B Garon, Michael Thomas   +2 more
exaly